Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: HARMONi-2
1. 系统已在2025-05-04 14:29:00对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
C Zhou, J Chen, L Wu, L Wang, A Xiong…
… on Lung Cancer, 2024
akesobio.com
… , double-blind, phase 3 study to compare the efficacy of … ; ivonescimab is approved in 2L EGFRm NSCLC in China. … survival; aNSCLC, advanced non-small cell lung cancer; PD-L1…